Take (BOM:532890) 3-Year ROIIC % : 4.19% (As of Mar. 2026) — 80% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532890 Take Ltd BOM:532890
38 GF Score
Price ₹21.01
! 3 Warning Signs
View Full Analysis

What is Take 3-Year ROIIC %?

Take BOM:532890 -4.98% 38 3-Year ROIIC % is 4.19 as of Mar. 2026, which is 80% above its 10-year median of 2.33. GuruFocus rates BOM:532890 with a GF Score™ of 38/100. The stock has 3 warning signs investors should review. Among 618 Healthcare Providers & Services companies, Take ranks better than 51.13% on this metric.

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Take's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 4.19%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Take's 3-Year ROIIC % or its related term are showing as below:

BOM:532890's 3-Year ROIIC % is ranked better than
51.13% of 618 companies
in the Healthcare Providers & Services industry
Industry Median: 3.535 vs BOM:532890: 4.19

Take  (BOM:532890) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Take 3-Year ROIIC % Related Terms


Take 3-Year ROIIC % Historical Data

* Premium members only.

The historical data trend for Take's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Take 3-Year ROIIC % Chart

Take Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.40 0.47 -9.62 -4.66 4.19

Take Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 4.19 0.00

BOM:532890 vs VEEV, BTSG, HQY: 3-Year ROIIC % Comparison

For the Health Information Services subindustry, Take's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Take 3-Year ROIIC % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Take's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Take's 3-Year ROIIC % falls into.


BOM:532890
38GF Score
Take Ltd BOM:532890
3-Year ROIIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Take 3-Year ROIIC % Calculation

Take's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -18.5280912 (Mar. 2026) - 58.19 (Mar. 2023) )/( 164.249 (Mar. 2026) - 1995.96 (Mar. 2023) )
=-76.7180912/-1831.711
=4.19%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Frequently Asked Questions Learn more about 3-Year ROIIC % →
What does a 3-Year ROIIC % of 4.19 mean?
Take (BOM:532890) has a 3-Year ROIIC % of 4.19 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Take and its competitors. This is 80% above median its historical median of 2.33. According to the industry distribution chart, Take ranks #302 out of 618 companies in the Healthcare Providers & Services industry, placing it in the top 48.9%.
Is Take's 3-Year ROIIC % too high?
Take's current 3-Year ROIIC % of 4.19 is 80% above median its 10-year median of 2.33. The Healthcare Providers & Services industry median 3-Year ROIIC % is 3.54. Take's value of 4.19 is 18.5% above this industry median. Based on the distribution chart, Take ranks #302 out of 618 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Take has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Take's 3-Year ROIIC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Take ranks #302 out of 618 companies for 3-Year ROIIC %. This puts Take in the upper half of its industry. The industry median 3-Year ROIIC % is 3.54. Take's value of 4.19 is 18.5% above this benchmark. While the company's 10-year median is 2.33 vs. the industry median of 3.54, Take has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.54, based on 618 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Take's current 3-Year ROIIC % of 4.19 is 18.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Take and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Take's current 3-Year ROIIC % is 4.19, which is 80% above median its own 10-year median of 2.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Take stock overvalued right now?
Take (BOM:532890) has a current 3-Year ROIIC % of 4.19. The current 3-Year ROIIC % is 4.19, which is 80% above median its 10-year median of 2.33 and 18.5% above the Healthcare Providers & Services industry median of 3.54. Take's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Take (BOM:532890), the current 3-Year ROIIC % is 4.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Take Business Description

Other Exchanges TAKE:India
Address No.56, Old No. 116, Dr. Radhakrishnan Salai, 4th Floor, Ragas Building, Mylapore, Chennai, TN, IND, 600004
Take Solutions Ltd is a technology solutions provider specializing in Life Sciences and Supply Chain Management services. The company offers integrated services including clinical research, generics support, regulatory affairs, pharmacovigilance, and data sciences. It supports pharmaceutical, biotech, and medical device companies to various countries with technology-backed solutions that enhance drug development and regulatory compliance. Revenue is driven by its broad portfolio of IT-enabled services focused on the life sciences industry and supply chain management, catering to a client base of innovators, generics manufacturers, and biotech firms.
38GF Score

Get the complete analysis for BOM:532890

3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹21.01
Price